ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis
about
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsPharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysisThe risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han populationPharmacogenetics and cardiovascular disease--implications for personalized medicineEvaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adultsHigh on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction.Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.Pharmacogenomics of anti-platelet and anti-coagulation therapy.Cardiovascular pharmacogenomics: expectations and practical benefits.Pharmacogenomics of oral antiplatelet drugs.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response.The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel.Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
P2860
Q26801867-C4FAE04C-27CE-4680-9BC3-708845817E7BQ26822796-5F39A459-3F93-4941-B826-900E804DF2DDQ27022443-14B1A4BD-C014-40F9-A372-12B7998F27F3Q35799847-676B950A-4391-4F98-A5B0-57DD8C6798BAQ36328226-3300E2A1-D5AF-4A5C-B57A-00E428912530Q36974672-1DB878B3-DA8E-41E4-A23D-C44D0186D8A7Q37167282-65E95E7C-7E97-4B12-BC5B-349104A05C39Q37680302-858D36D5-5E2A-4B0E-8B84-4A86BD60149AQ37724614-DB01271B-A8F9-4E89-B356-2125E332B040Q38116753-16D04E34-86C2-421D-980B-A599A007404EQ38169969-BE20CDA7-4EFE-451D-97E2-AD22315F9061Q38195628-798E85E2-EBC2-446F-B7DA-14B09EF5C752Q38307535-01CF85D0-9694-4935-8274-D506F472C1F0Q38414396-FAA95E45-5E92-4FEB-B6DA-3B811F7F7E14Q38734885-452A4ACE-B4FE-456A-A1C3-2D5FD1BFF380Q38750444-B0CCC162-0F5F-4610-9B1B-F2010B65E142Q38756642-3E4B6DC3-4031-4570-884A-48A386C1C1C7Q39249688-542439CF-D5CB-4831-9A36-85DD230F2032Q43097393-34FB0809-139A-4A75-84A5-5E4CF089C82EQ44547491-FEB6A0F1-8F51-40BD-A383-3D65B2FFE34DQ47094164-0C8C21BF-E062-4811-A446-AAC1E328CAD5Q47554139-51B6F51A-418F-4779-9632-284162E29C91Q48316634-964EF1D4-E673-4514-BF04-C499521B50E4Q51235778-C22DB918-86CB-4CDE-B1F2-82CEE19E70CFQ52322328-C83F80FD-E70B-4A55-824B-6BA2FC97E49FQ54627886-E2007875-3822-4F8D-B34E-1A58008EE95C
P2860
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
ABCB1 C3435T polymorphism and ...... CAD) patients: a meta-analysis
@ast
ABCB1 C3435T polymorphism and ...... CAD) patients: a meta-analysis
@en
ABCB1 C3435T polymorphism and ...... ent in coronary artery disease
@nl
type
label
ABCB1 C3435T polymorphism and ...... CAD) patients: a meta-analysis
@ast
ABCB1 C3435T polymorphism and ...... CAD) patients: a meta-analysis
@en
ABCB1 C3435T polymorphism and ...... ent in coronary artery disease
@nl
prefLabel
ABCB1 C3435T polymorphism and ...... CAD) patients: a meta-analysis
@ast
ABCB1 C3435T polymorphism and ...... CAD) patients: a meta-analysis
@en
ABCB1 C3435T polymorphism and ...... ent in coronary artery disease
@nl
P2093
P2860
P1433
P1476
ABCB1 C3435T polymorphism and ...... CAD) patients: a meta-analysis
@en
P2093
Renyuan Fang
Xiaojing Li
Xiaomin Chen
P2860
P304
P356
10.1371/JOURNAL.PONE.0046366
P407
P577
2012-10-09T00:00:00Z